Vitronectin in clotting factor IX concentrates.
Highly purified, plasma-derived factor IX (FIX) concentrates are produced in large part by a combination of anion exchange and heparin affinity chromatography. However, the concentrates still contain some accompanying proteins. The main impurity has turned out to be the adhesive glycoprotein, vitronectin. It occurs in concentrates exclusively in its multimeric form, in contrast to the situation in plasma. The multimeric vitronectin can be removed either by nanofiltration with a crossflow system or by size-exclusion chromatography. When these FIX concentrates are used as therapeutic agents, the fact has to be taken into account that considerable amounts of multimeric vitronectin are given to the patient. The physiological consequences of the dosage of this protein have not yet been investigated. Although no thrombogenicity has been reported in connection with the above-mentioned FIX concentrates, we recommend that the impurity should be removed from the preparation with the methods described here.
Josic
D
D
Octapharma Pharmazeutika Produktionsges m.b.H., Wien, Austria. djuro.josic@octapharma.at
Kannicht
C
C
Löster
K
K
Pock
K
K
Iberer
G
G
Buchacher
A
A
D001779:Blood Coagulation Factors / Q000737:chemistry / Q000302:isolation & purification / Q000592:standards*; D002851:Chromatography, High Pressure Liquid; D019281:Dimerization; D004340:Drug Contamination; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D019096:Vitronectin / Q000032:analysis* / Q000276:immunology / Q000378:metabolism
D001779:Blood Coagulation Factors; D019096:Vitronectin; C025667:prothrombin complex concentrates